Ganzhou Hemay Pharmaceutical Co., Ltd
12
4
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Role: lead
A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD
Role: lead
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
Role: lead
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment
Role: lead
Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets
Role: lead
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
Role: lead
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
Role: lead
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
Role: lead
Bioequivalence Test of Hemay005 Tablets
Role: lead
A Study to Evaluate the Effects of Single and Multiple Doses of Hemay005 Tablets in Health Caucasian Adult Volunteers
Role: lead
A Study of Hemay005 in Adult With Atopic Dermatitis
Role: lead
In Vivo Mass Balance Study of [14C]Hemay005
Role: lead
All 12 trials loaded